CompletedPhase 3NCT05843916
Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease
Studying Fabry disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Bio Sidus SA
- Principal Investigator
- Alberto A Fernández, MDInstituto de Investigaciones Clínicas Quilmes
- Intervention
- Recombinant human alpha galactosidase A (agalsidase beta)(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 16-60 years · All sexes
- Timeline
- 2022 – 2025
Study locations (5)
- Instituto de Nefrología Pergamino S.R.L, Pergamino, Buenos Aires, Argentina
- Centro Médico Santa María de la Salud, San Isidro, Buenos Aires, Argentina
- Instituto de Investigaciones Clínicas Quilmes, Buenos Aires, Argentina
- Clínica Universitaria Reina Fabiola, Córdoba, Argentina
- Centro Oncológico Riojano Integral, La Rioja, Argentina
Collaborators
Amsterdam UMC · IQVIA Solutions · IQVIA RDS Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05843916 on ClinicalTrials.govOther trials for Fabry disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06906367A Study of Patients With Fabry Disease (US Specific)Amicus Therapeutics
- RECRUITINGPHASE3NCT06904261A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA VariantsAmicus Therapeutics
- RECRUITINGNCT07235709Effect of Agalsidase Alfa on Cardiac Inflammation in Patients With Fabry Disease: A [18F]-FDG PET-CMR StudyYonsei University
- RECRUITINGNANCT07187440A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry DiseaseTakeda
- ENROLLING BY INVITATIONNANCT07495410Anderson-Fabry Disease Fitness Improvement Training: A-FAD-FITGeneral University Hospital, Prague
- RECRUITINGPHASE2, PHASE3NCT06328608A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry DiseaseChiesi Farmaceutici S.p.A.
- RECRUITINGNANCT07382128Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy PhenotypesIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGNCT06941025Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and BreastfeedingChiesi Farmaceutici S.p.A.